NBIX vs FOLD

For growth investors, Neurocrine Biosciences, Inc.

(NBIX) is the stronger pick with 21. 4% revenue growth year-over-year, versus 20. 0% for Amicus Therapeutics, Inc. (FOLD). Neurocrine Biosciences, Inc. (NBIX) offers the better valuation at 32. 0x trailing P/E (24. 1x forward), making it the more compelling value choice. Analysts rate Neurocrine Biosciences, Inc. (NBIX) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Neurocrine Biosciences, Inc.

is actually cheaper at 24. 1x.

Over the past 5 years, Neurocrine Biosciences, Inc.

(NBIX) delivered a total return of +64. 3%, compared to +48. 6% for Amicus Therapeutics, Inc. (FOLD). Over 10 years, the gap is even starker: NBIX returned +233. 2% versus FOLD's +119. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.

(FOLD) is the lower-risk stock at 0. 63β versus Neurocrine Biosciences, Inc. 's 0. 76β — meaning NBIX is approximately 20% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Neurocrine Biosciences, Inc. (NBIX) carries a lower debt/equity ratio of 13% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Neurocrine Biosciences, Inc.

(NBIX) is pulling ahead at 21. 4% versus 20. 0% for Amicus Therapeutics, Inc. (FOLD). On earnings-per-share growth, the picture is similar: Amicus Therapeutics, Inc. grew EPS 51. 2% year-over-year, compared to 41. 9% for Neurocrine Biosciences, Inc.. Over a 3-year CAGR, FOLD leads at 24. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Neurocrine Biosciences, Inc.

(NBIX) is the more profitable company, earning 16. 7% net margin versus -4. 3% for Amicus Therapeutics, Inc. — meaning it keeps 16. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NBIX leads at 21. 6% versus 5. 4% for FOLD. At the gross margin level — before operating expenses — NBIX leads at 98. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Neurocrine Biosciences, Inc.

(NBIX) trades at 24. 1x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 16. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NBIX: 19. 1% to $178. 09.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Amicus Therapeutics, Inc.

(FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63), +119. 2% 10Y return). Both have compounded well over 10 years (FOLD: +119. 2%, NBIX: +233. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.